# Trade Mark Journal No.2025/044 31 October 2025

## WO0000001880642 (5,42)

Office of origin: United States of America

Date of International Registration:4 September 2025
Date of designation in the UK: 4 September 2025

Class 5
  Pharmaceutical products for the treatment of cancer; pharmaceutical products for the treatment of lung cancer.
Class 42
  Research and development in the pharmaceutical and biotechnology fields.

ArriVent BioPharma, Inc.

Representative: Wade Savoy Outside General Counsel, LLP, 501 Boylston Street, 10th Floor, Boston MA 02116, UNITED STATES OF AMERICA